"versionIdentifier","instanceType","id","rationale","uuid:ID"
"2","StudyVersion","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","71b51631-6ba2-4cd0-bf6a-8491c108ba25"
